July 2015, Special ASCO Edition
Enhanced Reimbursement for Oncology Services Pays for Patient-Centered Care
Payment models that align reimbursement to support treatment planning and care coordination encourage oncology care providers to adhere to cancer treatment pathways, said Jennifer Malin, MD, PhD.
Anthem has a Cancer Care Quality Program that aligns practice patterns of physicians through enhanced reimbursement mechanisms. The providers qualify for enhanced reimbursement by adhering to a treatment regimen that is part of an evidence-based cancer treatment pathway.
âOncology practices today provide a whole range of services for patients, and typically that has been paid for by most payers out of the margin on the drugs,â said Malin, Medical Director, Oncology, Anthem, Indianapolis, IN. âWe started this program to shift the reimbursement towards more of a value-based reimbursement, so oncologists receive $350.00 per member per month when they are on a pathway. Itâs basically an alternate way of paying for the care coordination and treatment planning that they are already doing, but paying for it directly rather than through drug margins.â
The pathways are available on the Anthem website and include regimens for various cancers that are included in national guidelines. The pathways include about a half dozen treatment options proven to be effective and cost-effective.
âIn order to receive enhanced reimbursement, the oncologist has to select for one of our members one of those regimens that is on the pathway,â said Malin. âThis would last as long as their treatment regimen lasts.â
Practices register members with the Anthem Cancer Care Quality Program by entering data into a web-based platform operated by an Anthem subsidiary, AIM Specialty Health, and submit data on key clinical parameters, including cancer stage, pathology, biomarkers, planned treatment regimens, performance status, height, weight, and body mass index.
Ten Anthem health plan states are active in the program. An integrated database of claims captured from 6 participating commercial health plans and clinical data captured from participating practices and patients registered under the program were assessed. Altogether, 616 practices registered 5538 patients in the program between July 2014 and December 2014. The mean number of patients per practice was 8.7.
The most common cancer types were breast cancer (29%), lung cancer (15%), colorectal cancer (13%), and lymphoma (10%).
âThe goal of the program is to improve the quality of care for our members by decreasing the unwarranted variation [in care] and getting effective treatments, but also to prove value for our members, because when there are different regimens available that are equally effective but cost different amounts, the pathway includes the most cost-effective regimen,â she said.
Based on chemotherapy claims for members incurred only from September through October 2014, 64% of members (n = 2989) were registered with the program. Among registered patients, pathway adherence was 63% for breast cancer, 72% for colorectal cancer, and 63% for nonâsmall cell lung cancer.
âOur estimate through claims review prior to the program is that 40% to 50% of our patients were being treated according to pathway, and the data through the program show for the first 3 cancers, we came out with 63% to 74%,â she said.
Most requests for therapy were delivered within 2 weeks of submission for review. Within the first month, 75% of requests for breast cancer treatment, 78% of requests for colorectal cancer treatment, and 73% of requests for lung cancer treatment were delivered.
KRAS biomarkers were available for 40% of colorectal cancer patients, and EGFR biomarkers were available for 19% of lung cancer patients.
âThere are a lot of different reimbursement models out there that all involve shifting away from paying for drug margins to paying for more of a monthly management fee,â said Malin. âEach one has approached it slightly differently, but I think we will see more of a payment directly for the care and not having the payment tied to drugs.â
Lenvatinib Warrants Further Study in mRCC
Lenvatinib added to everolimus extended overall survival (OS) significantly compared with everoliÂmus alone in patients with metastatic renal cell carcinoma (mRCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone. The OS finding was a secondary end [ Read More ]
Pembrolizumab in Colorectal Cancer: Can Benefit Be Predicted?
New to the programmed death-1 (PD-1) inhibitor arena is coloÂrectal cancer, and for this tumor it may be possible to predict which patients will benefit from these drugs. In a phase 2 study of patients with colorectal cancer treated with pembrolizumab, the presence of mismatch repair (MMR) deficiency within the [ Read More ]